# Use Of GW274150 In The Prophylactic Treatment Of Migraine

> **NCT00242866** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 430 (actual)

## Conditions studied

- Migraine Disorders

## Interventions

- **DRUG:** GW274150
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT00242866
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-10
- **Primary completion:** 2007-09
- **Final completion:** 2007-09
- **Target enrollment:** 430 (ACTUAL)
- **Last updated:** 2016-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00242866

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00242866, "Use Of GW274150 In The Prophylactic Treatment Of Migraine". Retrieved via MORVS 2026-10-23 from https://api.morvs.ai/clinical/NCT00242866. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*